Ruxolitinib
Information
- Drug Name
- Ruxolitinib
- Description
- Entry(CIViC)
- 6
CIViC
Annotation
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04454658 | Active, not recruiting | Phase 1 | Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis | November 11, 2020 | November 2, 2024 |
| NCT03874052 | Active, not recruiting | Phase 1 | Ruxolitinib and Venetoclax in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | August 16, 2019 | December 31, 2024 |
| NCT04603495 | Active, not recruiting | Phase 3 | Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) | April 9, 2021 | December 2027 |
| NCT03722407 | Active, not recruiting | Phase 2 | Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion | August 28, 2019 | July 1, 2024 |
| NCT04551053 | Active, not recruiting | Phase 3 | To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304) | May 26, 2021 | July 31, 2024 |
| NCT03674047 | Active, not recruiting | Phase 2 | Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT) | April 19, 2019 | July 31, 2024 |
| NCT02493530 | Active, not recruiting | Phase 1 | TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea | July 2015 | December 2024 |
| NCT02494882 | Active, not recruiting | Phase 1 | Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older | June 29, 2015 | June 2025 |
| NCT02577926 | Active, not recruiting | Phase 2 | The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia | October 2015 | December 2028 |
| NCT03222609 | Active, not recruiting | Phase 2 | A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis | October 31, 2017 | February 2, 2029 |
| NCT04669210 | Active, not recruiting | Phase 2 | PTCy and Ruxolitinib vs PTCy, Tacrolimus and MMF in MUD and Haploidentical HSCT | November 3, 2020 | February 2025 |
| NCT04472598 | Active, not recruiting | Phase 3 | Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis | September 29, 2020 | October 19, 2032 |
| NCT04041050 | Active, not recruiting | Phase 1 | A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm | November 8, 2019 | January 29, 2025 |
| NCT03654768 | Active, not recruiting | Phase 2 | Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia | October 24, 2018 | July 1, 2028 |
| NCT05293717 | Active, not recruiting | Phase 1/Phase 2 | Topical Ruxolitinib in Chronic Hand Dermatitis | July 11, 2022 | December 31, 2024 |
| NCT02251821 | Active, not recruiting | Phase 2 | JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis | October 20, 2014 | December 28, 2025 |
| NCT03117751 | Active, not recruiting | Phase 2/Phase 3 | Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma | March 29, 2017 | March 31, 2028 |
| NCT04468984 | Active, not recruiting | Phase 3 | Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis | August 31, 2020 | November 3, 2031 |
| NCT04328844 | Active, not recruiting | Phase 1 | A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers | February 25, 2020 | April 2024 |
| NCT02723994 | Active, not recruiting | Phase 2 | A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia | September 30, 2016 | February 1, 2026 |
| NCT04807777 | Active, not recruiting | Phase 2 | Study of Ruxolitinib in Solid Organ Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma | July 8, 2021 | May 2025 |
| NCT03514069 | Active, not recruiting | Phase 1 | Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma | June 5, 2018 | December 31, 2024 |
| NCT02876302 | Active, not recruiting | Phase 2 | Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer | January 24, 2018 | August 2024 |
| NCT03427866 | Active, not recruiting | Phase 2 | Ruxolitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis. | August 28, 2018 | May 2025 |
| NCT04817007 | Active, not recruiting | Phase 1/Phase 2 | A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis) | March 22, 2021 | May 31, 2026 |
| NCT04551066 | Active, not recruiting | Phase 3 | To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313) | May 27, 2021 | July 31, 2024 |
| NCT02955940 | Active, not recruiting | Phase 2 | An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib | November 30, 2016 | December 31, 2024 |
| NCT02158858 | Active, not recruiting | Phase 1/Phase 2 | A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis | July 16, 2014 | October 31, 2024 |
| NCT05010005 | Active, not recruiting | Phase 1 | A Study of Ruxolitinib and Duvelisib in People With Lymphoma | August 12, 2021 | August 2025 |
| NCT04097821 | Active, not recruiting | Phase 1/Phase 2 | Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients | September 26, 2019 | July 31, 2024 |
| NCT03069326 | Active, not recruiting | Phase 2 | A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis | February 27, 2017 | February 2025 |
| NCT05722912 | Approved for marketing | Expanded Access of Ruxolitinib Cream to Treat a Single Patient With cGVHD | |||
| NCT03147742 | Approved for marketing | An Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant | |||
| NCT05269771 | Available | MAP to Provide Access to Ruxolitinib, for Patients With Polycythemia Vera | |||
| NCT04745637 | Available | Managed Access Programs for INC424, Ruxolitinib | |||
| NCT02292446 | Completed | Phase 3 | Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available. | November 21, 2014 | December 29, 2017 |
| NCT02370706 | Completed | Phase 1 | Study of the Safety of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 in Patients With Myelofibrosis | May 21, 2015 | November 9, 2020 |
| NCT00509899 | Completed | Phase 1/Phase 2 | Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis | June 2007 | February 2017 |
| NCT02400463 | Completed | Phase 2 | A Pilot Study of Ruxolitinib in Secondary Hemophagocytic Syndrome | February 5, 2016 | January 7, 2020 |
| NCT05663827 | Completed | Phase 3 | Ruxolitinib as add-on Therapy in Steroid-refractory Graft-vs-host Disease | January 1, 2019 | November 30, 2022 |
| NCT01369498 | Completed | Phase 2 | Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis | June 30, 2011 | September 24, 2014 |
| NCT02593760 | Completed | Phase 1 | A Study to Evaluate the Efficacy and Safety of Vismodegib in Combination With Ruxolitinib for the Treatment of Intermediate- or High-Risk Myelofibrosis (MF) | January 25, 2016 | July 12, 2017 |
| NCT05421104 | Completed | Ruxolitinib for Polycythemia Vera in Patients Resistant to or Intolerant of Hydroxyurea. | November 27, 2020 | June 29, 2021 | |
| NCT05410470 | Completed | Efficacy and Safety of Ruxolitinib in Patients With Myelofibrosis | August 2012 | December 2021 | |
| NCT02613598 | Completed | Phase 1 | Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma | May 12, 2016 | June 7, 2021 |
| NCT05121142 | Completed | Phase 1 | Study of Ruxolitinib for Acute and Chronic Graft Versus Host Disease | October 27, 2021 | May 13, 2023 |
| NCT02784496 | Completed | Phase 2 | Long-Term Side Effects of Ruxolitinib in Treating Patients With Myelofibrosis | September 29, 2016 | January 23, 2024 |
| NCT02806375 | Completed | Phase 1/Phase 2 | PTCy and Ruxolitinib GVHD Prophylaxis in Myelofibrosis | January 2016 | April 2019 |
| NCT05052385 | Completed | ECP Combination Study | April 13, 2021 | June 15, 2022 | |
| NCT02917096 | Completed | Phase 1 | Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With Myelofibrosis | November 13, 2016 | August 31, 2023 |
| NCT00617994 | Completed | Phase 2 | Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat Patients With Psoriasis | August 31, 2007 | May 31, 2009 |
| NCT02953678 | Completed | Phase 2 | A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1) | December 30, 2016 | August 14, 2019 |
| NCT02966353 | Completed | Phase 2 | Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients. | March 31, 2017 | February 15, 2019 |
| NCT03041636 | Completed | Phase 2 | Ruxolitinib Phosphate in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | March 8, 2017 | April 29, 2020 |
| NCT03112603 | Completed | Phase 3 | A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3) | June 29, 2017 | December 15, 2022 |
| NCT04921969 | Completed | Phase 3 | A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3) | July 19, 2021 | April 8, 2024 |
| NCT03144687 | Completed | Phase 2 | A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis | January 26, 2018 | June 1, 2021 |
| NCT02475655 | Completed | Phase 2 | Evaluating the Safety and Tolerability of Ruxolitinib in Antiretroviral-Treated HIV-Infected Adults | May 16, 2016 | April 4, 2018 |
| NCT01375140 | Completed | Phase 2 | Ruxolitinib and Lenalidomide for Patients With Myelofibrosis | September 22, 2011 | September 5, 2018 |
| NCT01392443 | Completed | Phase 2 | Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF | October 14, 2010 | October 31, 2017 |
| NCT04218071 | Completed | Phase 2 | Actuate 1901: 9-ING-41 in Myelofibrosis | August 20, 2020 | January 18, 2024 |
| NCT01423604 | Completed | Phase 2 | Study of Ruxolitinib in Pancreatic Cancer Patients | July 2011 | November 2016 |
| NCT01433445 | Completed | Phase 1 | Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis | November 1, 2011 | June 22, 2020 |
| NCT04281498 | Completed | Phase 2 | Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation | January 14, 2021 | May 30, 2023 |
| NCT01445769 | Completed | Phase 2 | Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis | September 2011 | April 2013 |
| NCT04338958 | Completed | Phase 2 | Ruxolitinib in Covid-19 Patients With Defined Hyperinflammation | April 22, 2020 | July 15, 2021 |
| NCT04374149 | Completed | Phase 2 | Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS | April 30, 2020 | December 1, 2020 |
| NCT04362137 | Completed | Phase 3 | Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm | May 2, 2020 | October 17, 2020 |
| NCT01594216 | Completed | Phase 2 | Ruxolitinib in Estrogen Receptor Positive Breast Cancer | April 2012 | April 9, 2016 |
| NCT01632904 | Completed | Phase 3 | Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study | June 2012 | May 2016 |
| NCT01693601 | Completed | Phase 1/Phase 2 | Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial) | January 2013 | May 18, 2018 |
| NCT01702064 | Completed | Phase 1 | Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients | February 21, 2013 | January 9, 2019 |
| NCT01712308 | Completed | Phase 2 | Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or Anemia | February 21, 2013 | May 24, 2022 |
| NCT01776723 | Completed | Phase 1/Phase 2 | A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib | February 20, 2013 | May 10, 2022 |
| NCT01877005 | Completed | Phase 2 | A Phase II Study of Oral JAK1/JAK2 Inhibitor INC424 in Adult Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma | July 4, 2013 | June 12, 2018 |
| NCT01895842 | Completed | Phase 1 | Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) | February 2014 | April 2, 2019 |
| NCT01914484 | Completed | Phase 1/Phase 2 | Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia | August 1, 2013 | December 31, 2018 |
| NCT01950780 | Completed | Phase 2 | Pilot Study to Evaluate the Efficacy of Ruxolitinib in Alopecia Areata | August 2013 | April 2016 |
| NCT01965119 | Completed | Phase 2 | Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-cell Lymphoma | November 15, 2013 | September 18, 2018 |
| NCT01969838 | Completed | Phase 3 | Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis | December 6, 2013 | May 2, 2019 |
| NCT01981850 | Completed | Phase 2 | A Phase 2 Study of RO7490677 In Participants With Myelofibrosis | October 1, 2013 | July 10, 2020 |
| NCT02015208 | Completed | Phase 1/Phase 2 | Ruxolitinib in the Treatment of Chronic Lymphocytic Leukemia | April 2014 | July 2015 |
| NCT02038036 | Completed | Phase 3 | Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy. | March 25, 2014 | April 7, 2020 |
| NCT02041429 | Completed | Phase 1/Phase 2 | Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca | February 2014 | January 2021 |
| NCT02049450 | Completed | Phase 2 | Study of Efficacy and Safety of INC424 in Regularly Transfused Patients With Thalassemia. | May 28, 2014 | April 12, 2016 |
| NCT02066532 | Completed | Phase 1/Phase 2 | Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer | June 2014 | October 14, 2020 |
| NCT02076191 | Completed | Phase 1/Phase 2 | Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML | February 2014 | July 20, 2018 |
| NCT02087059 | Completed | Phase 3 | A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis | April 2014 | April 2015 |
| NCT02155465 | Completed | Phase 1/Phase 2 | Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib | June 2014 | October 2017 |
| NCT02164500 | Completed | Phase 2 | JAK-inhibition in Recurrent Classical Hodgkin Lymphoma | October 2015 | May 17, 2019 |
| NCT02253277 | Completed | Phase 1 | Safety and Tolerability of Combined Treatment With Nilotinib and Ruxolitinib in CML and Ph+ ALL Patients | February 18, 2015 | April 3, 2018 |
| NCT02267278 | Completed | Phase 2 | Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF) | January 12, 2015 | June 1, 2018 |
| NCT03153982 | Completed | Phase 2 | Ruxolitinib in Operable Head and Neck Cancer | June 8, 2018 | October 18, 2023 |
| NCT04908280 | Completed | Phase 2 | Study of Ruxolitinib Cream for the Treatment of Discoid Lupus Erythematosus | May 4, 2022 | March 4, 2024 |
| NCT03491215 | Completed | Phase 1/Phase 2 | Study of Pharmacokinetics, Activity and Safety of Ruxolitinib in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease | February 21, 2019 | February 2, 2023 |
| NCT00934544 | Completed | Phase 3 | Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial | July 1, 2009 | March 4, 2015 |
| NCT00952289 | Completed | Phase 3 | COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial | August 2009 | October 2015 |
| NCT03616184 | Completed | Phase 2 | Study of Ruxolitinib in Sclerotic Chronic Graft-Versus-Host Disease After Failure of Systemic Glucocorticoids | September 5, 2018 | June 12, 2023 |
| NCT01317875 | Completed | Phase 1 | Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF) | March 31, 2011 | December 31, 2019 |
| NCT03773107 | Completed | Phase 1/Phase 2 | LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma | January 3, 2019 | February 21, 2024 |
| NCT01340651 | Completed | Phase 2 | Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients | March 2011 | July 2012 |
| NCT01348490 | Completed | Phase 2 | Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF) | June 15, 2011 | December 19, 2018 |
| NCT04530344 | Completed | Phase 3 | Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo | September 24, 2020 | November 14, 2022 |
| NCT04492618 | Completed | Phase 2 | Ruxolitinib Cream in the Treatment of Cutaneous Necrobiosis Lipoidica | September 29, 2020 | March 16, 2022 |
| NCT04055844 | Completed | Phase 2 | Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS | February 17, 2020 | September 6, 2022 |
| NCT04061876 | Completed | Phase 2 | First Line Therapy for High Risk Acute GVHD | August 25, 2019 | June 30, 2023 |
| NCT04355793 | No longer available | Expanded Access Program of Ruxolitinib for the Emergency Treatment of Cytokine Storm From COVID-19 Infection | |||
| NCT01730755 | No longer available | Ruxolitinib for Chuvash Polycythemia | |||
| NCT04337359 | No longer available | Ruxolitinib Managed Access Program (MAP) for Patients Diagnosed With Severe/Very Severe COVID-19 Illness | |||
| NCT06244862 | Not yet recruiting | Phase 2 | JAK Inhibitor in Acquired Hemophagocytic synDrome in the Intensive Care Unit | February 1, 2024 | February 1, 2026 |
| NCT06345495 | Not yet recruiting | Phase 2 | High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly | September 30, 2024 | January 1, 2029 |
| NCT06462469 | Not yet recruiting | Phase 4 | Study of Efficacy and Safety of Ruxolitinib in Patients With Grade II to IV Steroid-refractory Acute Graft vs. Host Disease | June 30, 2024 | November 5, 2026 |
| NCT06291987 | Not yet recruiting | Phase 1 | Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation | May 20, 2024 | May 2026 |
| NCT05566535 | Not yet recruiting | Changes in QoL and Symptoms in Patients With Polycythemia Vera Receiving Ruxo in a Routine Clinical Practice | October 1, 2022 | August 1, 2024 | |
| NCT06397313 | Not yet recruiting | Phase 2 | RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis | September 2024 | October 2027 |
| NCT05745714 | Not yet recruiting | Phase 1/Phase 2 | HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies | October 1, 2023 | October 1, 2030 |
| NCT05762640 | Not yet recruiting | Phase 2 | Ruxolitinib as First Line Treatment in Primary Haemophagocytic Lymphohistiocytosis (R-HLH) | March 2024 | November 2027 |
| NCT05762874 | Not yet recruiting | Ruxolitinib in Patients With Myelofibrosis | March 2023 | June 2025 | |
| NCT06075225 | Not yet recruiting | Phase 2 | MAP-guided Preemptive Therapy of aGvHD by Ruxolitinib | October 1, 2023 | September 30, 2026 |
| NCT06327100 | Not yet recruiting | Phase 2 | Open Label Phase 2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF) | September 30, 2024 | May 1, 2031 |
| NCT06388564 | Not yet recruiting | Phase 2 | A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease | July 8, 2024 | September 5, 2028 |
| NCT06364319 | Not yet recruiting | Phase 4 | Efficacy and Safety of Anti-CD25 rhMAb in the Treatment of Steroid-Refractory cGVHD | April 15, 2024 | June 30, 2028 |
| NCT06160791 | Not yet recruiting | Phase 2 | Ruxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH) | February 1, 2024 | May 31, 2027 |
| NCT06225310 | Not yet recruiting | Phase 1 | A Trial of Selinexor, Ruxolitinib and Methylprednisolone | March 1, 2024 | May 1, 2027 |
| NCT06233110 | Not yet recruiting | Phase 1 | Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD | September 1, 2024 | July 1, 2029 |
| NCT00044304 | Recruiting | Phase 2 | Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome | September 26, 2002 | January 1, 2026 |
| NCT02386800 | Recruiting | Phase 4 | CINC424A2X01B Rollover Protocol | March 5, 2015 | September 16, 2027 |
| NCT02928978 | Recruiting | Phase 2 | Ruxolitinib for Premalignant Breast Disease | May 13, 2018 | January 2025 |
| NCT02974647 | Recruiting | Phase 2 | Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma | November 2016 | November 2024 |
| NCT03286530 | Recruiting | Phase 2 | Ruxolitinib + Allogeneic Stem Cell Transplantation in AML | November 3, 2017 | December 2026 |
| NCT03558607 | Recruiting | Phase 1/Phase 2 | The Role of Ruxolitinib in Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Neoplasm | May 17, 2018 | August 31, 2024 |
| NCT03571321 | Recruiting | Phase 1 | Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia | May 28, 2019 | September 5, 2027 |
| NCT03610971 | Recruiting | Phase 2 | Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors | November 19, 2019 | January 2025 |
| NCT03681561 | Recruiting | Phase 1/Phase 2 | Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma | September 13, 2018 | December 2026 |
| NCT03801434 | Recruiting | Phase 2 | Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders | November 15, 2019 | November 30, 2025 |
| NCT03878199 | Recruiting | Phase 1/Phase 2 | Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms | February 20, 2019 | December 31, 2024 |
| NCT04116502 | Recruiting | Phase 3 | MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera | October 25, 2019 | February 1, 2028 |
| NCT04176198 | Recruiting | Phase 1/Phase 2 | A Study of Oral TP-3654 in Patients With Myelofibrosis | December 16, 2019 | April 30, 2030 |
| NCT04217356 | Recruiting | Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis | August 5, 2020 | February 5, 2026 | |
| NCT04269850 | Recruiting | Phase 1/Phase 2 | Fecal Microbiota Transplantation With Ruxolitinib and Steroids as an Upfront Treatment of Severe Acute Intestinal GVHD | September 1, 2019 | December 1, 2025 |
| NCT04279847 | Recruiting | Phase 1 | Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms | February 23, 2021 | December 31, 2024 |
| NCT04282187 | Recruiting | Phase 2 | Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms | March 24, 2020 | November 11, 2026 |
| NCT04303403 | Recruiting | Phase 1 | Study of Trametinib and Ruxolitinib in Colorectal Cancer and Pancreatic Adenocarcinoma | July 31, 2018 | March 31, 2024 |
| NCT04384692 | Recruiting | Phase 2 | Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis | December 18, 2020 | December 31, 2029 |
| NCT04455841 | Recruiting | Phase 1/Phase 2 | INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders | March 19, 2021 | June 30, 2026 |
| NCT04485260 | Recruiting | Phase 1/Phase 2 | An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib | January 28, 2021 | October 2024 |
| NCT04551131 | Recruiting | Phase 1/Phase 2 | Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis | July 13, 2021 | August 2026 |
| NCT04562389 | Recruiting | Phase 3 | Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis | March 11, 2021 | March 2028 |
| NCT04644211 | Recruiting | Phase 2 | Ruxolitinib in Thrombocythemia and Polycythemia Vera | March 21, 2022 | December 2024 |
| NCT04744116 | Recruiting | Early Phase 1 | Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease | February 17, 2021 | March 15, 2026 |
| NCT04908735 | Recruiting | Phase 2 | Ruxolitinib for Early Lung Dysfunction After Hematopoietic Stem Cell Transplant | November 12, 2021 | November 2025 |
| NCT05088356 | Recruiting | Phase 1 | Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft | September 7, 2021 | December 2025 |
| NCT05280509 | Recruiting | Phase 1/Phase 2 | Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib | June 9, 2022 | April 2027 |
| NCT05371964 | Recruiting | Phase 1 | A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis | May 4, 2022 | August 2027 |
| NCT05398809 | Recruiting | Phase 2 | Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata | January 18, 2023 | December 1, 2027 |
| NCT05413356 | Recruiting | Phase 2 | Ruxolitinib for Newly Diagnosed Bronchiolitis Obliterans Syndrome | June 1, 2022 | January 1, 2025 |
| NCT05440942 | Recruiting | Phase 1 | Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma | January 19, 2023 | September 2027 |
| NCT05447260 | Recruiting | Phase 4 | A New Prognostic Stratification-based Safety and Efficacy Study of Ruxolitinib in Myelofibrosis | June 10, 2022 | December 10, 2023 |
| NCT05491304 | Recruiting | Phase 4 | Cytokine Guided Risk Stratification and Treatment in Pediatric Hemophagocytic Lymphohistiocytosis | September 1, 2022 | December 31, 2025 |
| NCT05548062 | Recruiting | Study to Identify and Describe Predictive Factors for Thromboembolic Events in Patients With High-risk Polycythemia Vera | March 2, 2023 | September 30, 2026 | |
| NCT05579769 | Recruiting | Phase 2 | A Phase II Pediatric Study of a Graft-VS.-Host Disease (GVHD) Prophylaxis Regimen With no Calcineurin Inhibitors After Day +60 Post First Allogeneic Hematopoietic Cell Transplant for Hematological Malignancies | November 4, 2022 | April 2027 |
| NCT05592015 | Recruiting | Phase 2 | Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia | May 3, 2023 | December 31, 2025 |
| NCT05599256 | Recruiting | Phase 2 | Prevention of Severe Acute Graft-versus-host Disease in Pediatric Patients Using a daGOAT Model | February 9, 2023 | December 1, 2025 |
| NCT05600855 | Recruiting | Phase 2 | Prevention of Severe Acute Graft-versus-host Disease in Adult Patients Using a daGOAT Model | January 15, 2023 | December 1, 2025 |
| NCT05621733 | Recruiting | A PMS of Jakavi® in Patients With Steroid-Refractory Graft-versus-Host Disease (SR-GvHD) in Korea | April 7, 2023 | May 13, 2026 | |
| NCT05622318 | Recruiting | Phase 2 | De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis | August 29, 2023 | December 15, 2025 |
| NCT05714072 | Recruiting | Phase 1 | A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis | January 25, 2023 | January 2025 |
| NCT05870475 | Recruiting | Phase 2 | Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV | May 30, 2023 | May 31, 2028 |
| NCT05936359 | Recruiting | Phase 1 | A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms | September 25, 2023 | February 29, 2028 |
| NCT05980806 | Recruiting | Phase 2 | A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia | April 22, 2024 | October 2028 |
| NCT05998395 | Recruiting | Phase 1/Phase 2 | JAK/STAT Inhibition in CNS Kohlmeier-Degos Disease | September 28, 2023 | March 15, 2025 |
| NCT05998408 | Recruiting | Phase 1/Phase 2 | JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow Failure | February 20, 2024 | June 3, 2032 |
| NCT06008808 | Recruiting | Phase 1 | Ruxolitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation | May 7, 2024 | December 11, 2026 |
| NCT06079879 | Recruiting | Phase 3 | A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006) | December 31, 2023 | August 18, 2028 |
| NCT06199427 | Recruiting | Phase 2 | PTCy and and Ruxolitinib for GVHD Prophylaxis After HSCT With Thymoglobulin in Conditioning Regimen in Patients With Inborn Errors of Immunity | November 21, 2023 | December 31, 2027 |
| NCT06457425 | Recruiting | Phase 2 | Flunotinib Maleate Phase II Intermediate-High Risk Bone Fiber Clinical Trial | May 6, 2024 | July 6, 2026 |
| NCT02120417 | Terminated | Phase 2 | A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer | May 2014 | January 2017 |
| NCT02119650 | Terminated | Phase 2 | Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer | February 11, 2014 | June 21, 2016 |
| NCT00726232 | Terminated | Phase 2 | Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential Thrombocythemia | August 20, 2008 | August 20, 2018 |
| NCT04331665 | Terminated | N/A | Study of the Efficacy and Safety of Ruxolitinib to Treat COVID-19 Pneumonia | May 21, 2020 | March 24, 2021 |
| NCT04480086 | Terminated | Phase 1 | Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis | March 17, 2021 | July 28, 2023 |
| NCT02117479 | Terminated | Phase 3 | Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1) | March 2014 | December 2016 |
| NCT04543279 | Terminated | Phase 2 | Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia | May 3, 2021 | July 30, 2022 |
| NCT03878524 | Terminated | Phase 1 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | April 1, 2020 | December 10, 2020 |
| NCT00638378 | Terminated | Phase 2 | Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer | February 2008 | January 2009 |
| NCT02091752 | Terminated | Phase 2 | A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial) | September 2014 | February 2015 |
| NCT02436135 | Terminated | Phase 1 | Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed Disease | June 5, 2015 | November 20, 2017 |
| NCT02072057 | Terminated | Phase 2 | Study of Ruxolitinib in the Treatment of Cachexia in Patients With Tumor-Associated Chronic Wasting Diseases. | April 20, 2014 | November 30, 2018 |
| NCT03515200 | Terminated | Phase 1 | Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia | April 20, 2018 | July 29, 2020 |
| NCT03386214 | Terminated | Phase 1 | Pevonedistat in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis | April 23, 2018 | October 4, 2021 |
| NCT03373877 | Terminated | Phase 1 | Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis | May 24, 2018 | March 10, 2020 |
| NCT02152956 | Terminated | Phase 1/Phase 2 | Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML) | June 9, 2014 | July 5, 2022 |
| NCT03123588 | Terminated | Phase 2 | Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272) | November 14, 2017 | August 3, 2020 |
| NCT04934670 | Terminated | Phase 3 | A Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT CTN 2002) | June 16, 2022 | January 19, 2023 |
| NCT02718300 | Terminated | Phase 2 | A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis | February 8, 2017 | April 29, 2022 |
| NCT02711137 | Terminated | Phase 1/Phase 2 | Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies | May 18, 2016 | February 13, 2019 |
| NCT02119676 | Terminated | Phase 2 | Study of Ruxolitinib in Colorectal Cancer Patients | March 2014 | December 2016 |
| NCT02119663 | Terminated | Phase 3 | A Study of Ruxolitinib in Pancreatic Cancer Patients | June 2014 | October 2016 |
| NCT01822756 | Terminated | Phase 1 | An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors | April 2013 | August 2016 |
| NCT02598297 | Terminated | Phase 3 | Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations. | February 3, 2016 | October 23, 2017 |
| NCT01751425 | Terminated | Phase 1 | Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors | July 24, 2013 | September 24, 2019 |
| NCT01712659 | Terminated | Phase 1/Phase 2 | Ruxolitinib for Adult T-Cell Leukemia | October 26, 2012 | January 18, 2022 |
| NCT01620216 | Terminated | Phase 2 | Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia | May 11, 2012 | April 30, 2017 |
| NCT01562873 | Terminated | Phase 2 | Ruxolitinib in Patients With Breast Cancer | June 2012 | June 2016 |
| NCT02587598 | Terminated | Phase 1/Phase 2 | Study of INCB053914 in Subjects With Advanced Malignancies | December 29, 2015 | August 11, 2020 |
| NCT01251965 | Terminated | Phase 1/Phase 2 | Phase l/II Study of Ruxolitinib for Acute Leukemia | December 2010 | July 2012 |
| NCT04377620 | Terminated | Phase 3 | Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT) | May 24, 2020 | February 26, 2021 |
| NCT03613428 | Unknown status | Phase 1/Phase 2 | Ruxolitinib Plus LVP in Patients With R/R ETP-ALL | December 1, 2018 | March 30, 2021 |
| NCT04446806 | Unknown status | Phase 4 | Prevention and Treatment of Differentiation Syndrome in Patients With Acute Promyelocytic Leukemia | June 1, 2019 | May 31, 2021 |
| NCT03795909 | Unknown status | Phase 1/Phase 2 | Ruxolitinib Combined With Dexamethasone for HLH | March 1, 2017 | March 1, 2022 |
| NCT05021276 | Unknown status | Phase 4 | Basiliximab Combined With Ruxolitinib as Second-line Treatment of Grade 3-4 Steroid-resistant aGVHD | December 15, 2020 | December 15, 2022 |
| NCT04009525 | Unknown status | Phase 4 | Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major: A Multicenter, Prospective Clinical Study | June 1, 2019 | May 31, 2023 |
| NCT03669965 | Unknown status | Phase 2 | KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera | January 15, 2019 | October 2022 |
| NCT03959371 | Unknown status | Ruxolitinib in Myelofibrosis Patients in Lombardy, Italy | April 11, 2017 | December 31, 2021 | |
| NCT02912754 | Unknown status | Phase 1/Phase 2 | Ruxolitinib Combined With Ibrutinib in Chronic Lymphocytic Leukemia Patients | March 2017 | August 2019 |
| NCT05137496 | Unknown status | Phase 3 | Ruxolitinib and Methylprednisolone as a First-line Treatment for Macrophage Activation Syndrome | June 1, 2022 | June 1, 2024 |
| NCT02638428 | Unknown status | Phase 2 | Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy | December 2015 | December 2023 |
| NCT04581954 | Unknown status | Phase 1/Phase 2 | Inflammatory Signal Inhibitors for COVID-19 (MATIS) | October 2, 2020 | June 30, 2022 |
| NCT04354714 | Withdrawn | Phase 2 | Ruxolitinib to Combat COVID-19 | June 30, 2020 | December 31, 2021 |
| NCT04016116 | Withdrawn | Phase 2 | Dual PD-1 and JAK2 Inhibition in Hematological Malignancies | December 2019 | December 2021 |
| NCT02973711 | Withdrawn | Phase 1/Phase 2 | A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML | January 2018 | August 2021 |
| NCT04348071 | Withdrawn | Phase 2/Phase 3 | Safety and Efficacy of Ruxolitinib for COVID-19 | July 2021 | October 2021 |
| NCT04354727 | Withdrawn | Phase 1/Phase 2 | A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy | December 15, 2020 | June 15, 2023 |
| NCT05909943 | Withdrawn | Phase 1/Phase 2 | Efficacy and Safety of Ruxolitinib in Neuromyelitis Optica Spectrum Disorders | June 1, 2024 | August 1, 2026 |
| NCT02593929 | Withdrawn | Early Phase 1 | Pharmacodynamic Effects and Predictive Biomarkers With Ruxolitinib in Operable Head and Neck Cancer | January 2017 |
- Trade name (Drug list of Screening Committee of Anticancer Drugs)
- Jakafi
- US Approved Year (20160209) (Drug list of Screening Committee of Anticancer Drugs)
- 2011
- Japan Approved Year (20160209) (Drug list of Screening Committee of Anticancer Drugs)
- 2014
- Target (Drug list of Screening Committee of Anticancer Drugs)
- JAK
- Disease name (Drug list of Screening Committee of Anticancer Drugs)
- 骨髄線維症